2024
“Recovery is about change, so you have to change everything”: Exploring the evolution of recovery capital among women in substance use disorder treatment
Jadovich E, Viera A, Edelman E, Muilenburg J, Kershaw T. “Recovery is about change, so you have to change everything”: Exploring the evolution of recovery capital among women in substance use disorder treatment. SSM - Qualitative Research In Health 2024, 5: 100422. PMID: 40060368, PMCID: PMC11883845, DOI: 10.1016/j.ssmqr.2024.100422.Peer-Reviewed Original ResearchSubstance use disorder treatmentRecovery capitalSecondary qualitative analysis of dataDisorder treatmentNon-clinical interventionsCommunity capitalSubstance use disordersSecondary qualitative analysisSubstance use disorder recoveryIndirect effects of treatmentExperiences of womenEffects of treatmentSubstance use researchRecovery capital frameworkAddiction researchQualitative analysis of dataStudy time pointsThematic analysisClinical pathwayParticipants' experiencesTreatment programsDisorder recoveryWomen's experiencesCapital frameworkCapital development
2010
A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis
Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis. JAMA Neurology 2010, 67: 1055-1061. PMID: 20837847, PMCID: PMC2954052, DOI: 10.1001/archneurol.2010.222.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdrenergic beta-AgonistsAdultAlbuterolDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleGlatiramer AcetateHumansInterferon-gammaInterleukin-13Logistic ModelsMaleMiddle AgedMultiple Sclerosis, Relapsing-RemittingOdds RatioPeptidesPilot ProjectsTreatment OutcomeConceptsMultiple Sclerosis Functional CompositeRelapsing-remitting multiple sclerosisGlatiramer acetateMultiple sclerosisClinical trialsAlbuterol groupTime pointsOral doseIL-13Subcutaneous injectionHelper T-cell subtypes 1Double-masked clinical trialGlatiramer acetate treatmentImmunologic end pointsMasked clinical trialEffects of albuterolIL-12 expressionIL-13 productionStudy time pointsΒ2-adrenergic agonistAlbuterol treatmentAcetate therapyAdverse eventsFirst relapseImmunologic effects
2009
Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder.
Coric V, Stock EG, Pultz J, Marcus R, Sheehan DV. Sheehan Suicidality Tracking Scale (Sheehan-STS): Preliminary Results from a Multicenter Clinical Trial in Generalized Anxiety Disorder. Innov Clin Neurosci 2009, 6: 26-31. PMID: 19724740, PMCID: PMC2719443.Peer-Reviewed Original ResearchClinical trialsHAM-D itemsGeneralized anxiety disorderSheehan Suicidality Tracking ScaleSuicidal thoughtsWeek 8Suicidal ideationCorticotropin-releasing factor antagonistAnxiety disordersTreatment-emergent suicidal ideationActive comparator studiesExploratory outcome measuresClinician-Administered Rating ScaleMulticenter clinical trialStudy time pointsScale total scoreLarger study sampleComparator studiesStudy protocolMean changeOutcome measuresWeek 4Prospective assessmentFactor antagonistsClinical care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply